Securities ▲▼ | Shares | Value | |||||
|---|---|---|---|---|---|---|---|
Q3 2024 ▲▼ | Q4 2024 ▲▼ | Change ▲▼ | Q3 2024 ▲▼ | Q4 2024 ▲▼ | Weight (%) ▲▼ | Change ▲▼ | |
| Arcellx, Inc. COMMON STOCK | 2,346,630 | 2,346,630 | 0 | $195.97M | $179.96M | 43.88% | -$16.00M |
| ARS Pharmaceuticals, Inc.(SPRY) | 4,012,903 | 4,012,903 | 0 | $58.19M | $42.34M | 10.32% | -$15.85M |
| CRISPR Therapeutics AG(CRSP) | 1,048,951 | 1,048,951 | 0 | $49.28M | $41.29M | 10.07% | -$7.99M |
| Design Therapeutics, Inc.(DSGN) | 6,526,476 | 6,526,476 | 0 | $35.11M | $40.27M | 9.82% | +$5.16M |
| Zenas BioPharma, Inc.(ZBIO) | 4,911,539 | 4,911,539 | 0 | $83.10M | $40.23M | 9.81% | -$42.88M |
| Mineralys Therapeutics, Inc.(MLYS) | 2,016,822 | 2,016,822 | 0 | $24.42M | $24.83M | 6.05% | +$403.4K |
| Alumis Inc. | 1,959,896 | 1,959,896 | 0 | $20.93M | $15.40M | 3.76% | -$5.53M |
| Oruka Therapeutics, Inc.(ORKA) | 375,330 | 430,330 | +55,000 | $9.20M | $8.34M | 2.03% | -$855.2K |
| Nkarta, Inc.(NKTX) | 3,333,333 | 3,333,333 | 0 | $15.07M | $8.30M | 2.02% | -$6.77M |
| enGene Holdings Inc. COM | 747,750 | 747,750 | 0 | $4.94M | $4.97M | 1.21% | +$37.4K |
| KALA BIO, Inc.(KALA) | 443,661 | 598,940 | +155,279 | $2.53M | $4.16M | 1.01% | +$1.63M |